(CANF) Completes Phase II/III Trial for CF101 in Treatment of Psoriasis

Data expected to be released in Q1 2015

PETACH TIKVA, Israel, Feb. 4, 2015 — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company’s drug candidate CF101 have completed the study’s 32 week treatment protocol. The trial has been completed and the final data is ready for analysis. The Company plans to publish top line results by the end of March 2015.  Interim results from this Phase II/III trial and final results from the prior Phase II trial for CF101 in psoriasis were both positive.

“Following a thorough analysis of the data over the coming weeks, we look forward to announcing top line results on the efficacy and safety of CF101 in the treatment of moderate-to-severe plaque psoriasis. If these results are in line with the previously published favorable interim data, then we believe CF101 could offer a much-needed treatment alternative to patients living with psoriasis,” stated Can-Fite CEO Dr. Pnina Fishman.

The psoriasis therapeutic market is dominated by biological drugs that are primarily administered via intravenous injection (IV) and have potential side effects. According to Global Data, the psoriasis treatment market was worth $3.6 billion in 2010 and is forecast to grow to $6.7 billion by 2018.

This Phase II/III double-blind, placebo-controlled study is designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis. Can-Fite enrolled 326 patients through 17 clinical centers in the U.S., Europe, and Israel. The first study cohort was comprised of three arms with patients receiving: 1 mg of CF101; 2 mg of CF101; and placebo. All patients receiving placebo were switched to either 1 mg or 2 mg of CF101 after 12 weeks. The primary efficacy endpoints are a statistically significant improvement in standard measures used by dermatologists to assess psoriasis including the Psoriasis Area Sensitivity Index (PASI) score and the secondary end points among others are the Physicians’ Global Assessment (PGA) score as well as various safety parameters.

About Psoriasis

Psoriasis is a skin condition that affects 2% to 3% of the general population according to the National Psoriasis Foundation. The disease is manifested by scaly plaques on the skin and in the severe form has a major effect on the physical and emotional well-being of the patients. Topical agents are typically used for mild disease, phototherapy for moderate disease, and systemic agents for severe disease. For moderate to severe cases, systemic biologic drugs, delivered via IV, have dominated the market. According to the National Psoriasis Foundation, common side effects of biologics include respiratory infections, flu-like symptoms, and injection site reactions while rare side effects include serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, blood disorders, and certain types of cancer. We believe a significant need remains for novel oral and safe drugs for patients who do not respond to existing therapies or for whom these therapies are unsuitable.

About CF101

CF101, an A3 adenosine receptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies. CF101 is currently developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (completed Phase II) and psoriasis (Phase II/III).

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company’s CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite’s liver cancer drug CF102 is in Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. The Company’s CF602 has shown efficacy in the treatment of erectile dysfunction. Can-Fite has initiated a full pre-clinical program for CF602 in preparation for filing an IND with the U.S. FDA in this indication.  These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite’s filings with the SEC and in its periodic filings with the TASE.  In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.  Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Can-Fite BioPharma

Motti Farbstein

info@canfite.com

+972-3-9241114

(SMRT) Announces Special Dividend and $275 Million Credit Facility

JACKSONVILLE, Fla., Feb. 4, 2015  — Stein Mart, Inc. (Nasdaq:SMRT) announced today that its Board of Directors declared a special dividend of $5.00 per common share, payable on February 27, 2015 to shareholders of record as of the close of business on February 13, 2015. The aggregate amount of payment to be made in connection with this special dividend will be approximately $230 million. The special dividend will be funded by existing cash and the credit facilities discussed below. It is the Company’s intent to continue its regular quarterly cash dividend of $0.075 per share.

Stein Mart also announced that it has entered into a second amended and restated credit agreement (the “Credit Agreement”) with Wells Fargo Bank that will mature in February 2020 and a master loan agreement with Wells Fargo Equipment Finance, Inc. (the “Equipment Term Loan” and, together with the Credit Agreement, the “Credit Facilities”). The Credit Facilities replace the Company’s former $100 million senior secured revolving credit facility which was set to mature on February 28, 2017. The Credit Facilities (i) increase the revolving credit facility to $250 million, (ii) add a $25 million equipment term loan that matures 36 months following date of disbursement, (iii) provide better pricing terms, and (iv) extend the maturity date of the former revolving credit facility. Borrowings under the Credit Facilities will primarily be used for a special dividend, but may also be used for working capital, capital expenditures and general corporate purposes.

After payment of the dividend, the Company’s debt will fluctuate between approximately $150 and $200 million in 2015 based on seasonal working capital needs. Interest expense for 2015 is estimated to be approximately $3.5 to $4.0 million based on current interest rates.

“Today’s announcement of a $5.00 special dividend reflects our continued generation of strong cash flows and favorable access to the credit markets which allow us to return value to our shareholders,” said Jay Stein, Chief Executive Officer. “Even after this special dividend, we will have ample capital capacity to make long-term investments in our business, such as our accelerated store expansion.”

About Stein Mart

Stein Mart stores offer the fashion merchandise, service and presentation of a better department or specialty store, at prices competitive with off-price retail chains. With locations from California to Massachusetts, as well as steinmart.com, Stein Mart’s focused assortment of merchandise features current season, moderate to better fashion apparel for women and men, as well as accessories, shoes and home fashions. In 2014, Stein Mart was voted America’s “Best Department Store” by the readers of USA TODAY.

Cautionary Statement Regarding Forward-Looking Statements

Except for historical information contained herein, the statements in this release may be forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company does not assume any obligation to update or revise any forward-looking statements even if experience or future changes make it clear that projected results expressed or implied will not be realized. Forward-looking statements involve known and unknown risks and uncertainties that may cause Stein Mart’s actual results in future periods to differ materially from forecasted or expected results. Those risks include, without limitation:

• consumer sensitivity to economic conditions
• competition in the retail industry
• changes in consumer preferences and fashion trends
• ability to negotiate acceptable lease terms with current and potential landlords
• ability to successfully implement strategies to exit under-performing stores
• extreme and/or unseasonable weather conditions
• adequate sources of merchandise at acceptable prices
• dependence on certain key personnel and ability to attract and retain qualified employees
• increases in the cost of employee benefits
• disruption of the Company’s distribution process
• information technology failures
• data security breaches
• acts of terrorism
• ability to adapt to new regulatory compliance and disclosure obligations
• material weaknesses in internal control over financial reporting
• other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission.

SMRT-F

Additional information about Stein Mart, Inc. can be found at www.steinmart.com

CONTACT: For more information:
         Linda Tasseff
         Director, Investor Relations
         (904) 858-2639
         ltasseff@steinmart.com

(ANY) Glassware Delivers Solutions for Digital Learning Environments

Glassware 2.0 Future Proofs Texas School District’s Investment in 10,000+ Devices for a 1 to 1 Student Deployment

SAN JOSE, Calif., Feb. 4, 2015  — Sphere 3D Corporation (Nasdaq:ANY) today announced the availability of Glassware 2.0® for deployment in K-12 schools that are looking to deliver Windows application workspaces in support of a variety of devices—such as Android®, Chromebook, iPad®, OS X® and Windows RT®—and can work within an existing IT infrastructure or operate as a standalone solution.

“We tried traditional virtualization techniques but the specific applications we needed couldn’t virtualize or wouldn’t scale. With our Glassware 2.0 enabled Dell™ server, we were able to virtualize the applications we needed and future proof our investment in Chromebooks for our students,” commented Dustin Hardin, Director of Technology of New Caney ISD, a current Glassware customer. “Having the ability to securely deliver virtualized Windows-based applications to our students allows us to plan around our own technology roadmap instead of having to rely on multiple software vendors to release compatible versions or maintain support for existing versions already in use by our schools.”

According to the National Center for Education Statistics 2014 report there are approximately 49.8 million K-12 students, 98,300 public schools and 13,600 public school districts in the U.S alone. The majority of schools have labs filled with antiquated workstations and are migrating to or considering migrating to BYOD deployments or a 1 to 1 program with district-issued devices in student backpacks. The new devices are more mobile, less expensive, run on a variety of different operating systems, and far outnumber the workstations used before. For example, a school may migrate from 30 workstations running Windows XP to over 1,000 Chromebooks running the lightweight Chrome OS. In addition, a majority of these school districts face increased pressure to migrate from workstations to less expensive and more mobile devices.

Unfortunately, many of these devices don’t play well with current software which was written for a workstation dominated world and used for everything from digital learning to legislated standardized proficiency testing. Educational software companies have been overwhelmed by the need to deliver multiple platform support—writing a version of the application for iOS, a version for Chromebook and a version for Surface RT etc. In addition, many current applications require Internet access to sync with offsite data centers and use various plugins, Java and/or Flash software that is not supported by student devices, or will only work if security is disabled on students’ computers. Traditional virtualization solutions have not worked out because of their inability to virtualize many of these critical applications or deliver them economically or at scale.

Glassware 2.0 is delivered on one or multiple servers that can be placed at the school or the district’s data center. The Glassware 2.0 appliance allows school districts to quickly deliver Windows® workspaces, to most devices in use today, and further allows for secure access to portals for high stakes standardized testing, regardless of whether the portal is accessed by Internet Explorer, Safari, Chrome or a number of other browsers. Finally, Glassware provides licensing simplicity through Microsoft® embedded licensing on all Glassware appliances while enabling simple and flexible deployment options for IT administrators.

“Dustin, and the team at New Caney ISD, recognized that an increased access to technology will augment the learning experience for students in their district and moved forward to become one of the largest 1 to 1 Chromebook deployments in the K-12 segment with over 14,000 students with devices,” stated Peter Tassiopoulos, President of Sphere 3D. “We recognize that technology is quickly becoming part of the fabric of student life and are partnering with thought leaders and organizations like New Caney to pave the way for an immersive digital experience, both in the schools and from home.”

Glassware Demonstration Today

Dustin Hardin will be presenting and demonstrating Sphere 3D’s Glassware 2.0 virtualization technology today at the TCEA 2015 Convention & Exposition in Austin, Texas at 8:00a.m. CST and again at 12:00p.m. CST. TCEA is a member-based organization devoted to the use of technology in education. The 2015 conference is focused on passionate teachers, campus and district leaders gathering to share the latest trends and best practices for technology in education.

About Glassware 2.0 and Sphere 3D

Sphere 3D’s Glassware 2.0™ platform delivers virtualization of some of the most demanding applications in the marketplace today, making it easy to move applications from a physical PC or workstation to a virtual environment delivered to the user workspace on Chromebooks, tablets, Smartphones and a host of other devices.

Sphere 3D Corporation (Nasdaq:ANY) is a virtualization technology solution provider with a portfolio of products that address the complete data continuum from active data to data at rest. Dedicated to continue to lead through innovation, Sphere 3D enables the integration of virtual applications, virtual desktops, and storage into workflow, and allows organizations to deploy a combination of public, private or hybrid cloud strategies. Sphere 3D’s V3 converged infrastructure solutions include one of the industry’s first purpose-built appliances for virtualization and the Desktop Cloud Orchestrator management software for VDI. Overland Storage and Tandberg Data, wholly-owned subsidiaries of Sphere 3D, provide an integrated range of technologies and services for primary, nearline, offline, and archival data storage that make it easy and cost-effective to manage different tiers of information over the data lifecycle. For additional information, visit www.sphere3d.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve risks, uncertainties, and assumptions that are difficult to predict. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties including, without limitation, any increase in our cash needs; possible actions by customers, suppliers, competitors or regulatory authorities; other risks detailed in the Form F-4/A we filed with the SEC; and other risks detailed from time to time in our periodic reports contained in our Annual Information Form and other filings with Canadian securities regulators (www.sedar.com) and in prior periodic reports filed with the United States Securities and Exchange Commission (www.sec.gov). We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

CONTACT: Media Contact:
         Pattie Adams
         Director, Global Corporate Communications
         +1 408/283-4779
         padams@overlandstorage.com

         Investor Contact:
         MKR Group Inc.
         Todd Kehrli or Jim Byers
         +1 323/468-2300
         ovrl@mkr-group.com

(OHGI) Rollout of the Aishuo App in China

(APDNW) Demonstrates Multi-Modal In-Field Detection System

Reader Platform Offers On-the-Spot Mark Detection and Validation as Stand-Alone or Part of APDN’s digitalDNA(R) System, Making History in Authentication

(SPEX) Board Unanimously Rejects Unsolicited Proposal from Marathon Patent Group

Marathon Proposal Substantially Undervalues Spherix and is Not in the Best Interests of Stockholders

BETHESDA, Md., Feb. 3, 2015  — Spherix Incorporated (SPEX), an intellectual property development company committed to the fostering and monetization of intellectual property, today announced that its Board of Directors has considered and unanimously rejected an unsolicited proposal (the “Proposal”) received from Marathon Patent on January 15, 2015 indicating Marathon’s interest in acquiring Spherix in a stock-for-stock transaction valuing Spherix at a 15% premium above the recent market price of Spherix’s common stock. After a comprehensive review, conducted in consultation with its legal advisors, the Spherix Board concluded that the Proposal substantially undervalues Spherix, creates significant risks and uncertainties for the stockholders of Spherix, and is not in the best interests of the Company and its stockholders.

“After careful review and consideration, our Board of Directors has unanimously determined that Marathon’s unsolicited proposal substantially undervalues Spherix and does not reflect the value of the Company’s patent portfolio and its current business. We continue to execute our business plan and believe our assets put the company in its best position to be successful” said Anthony Hayes, CEO of Spherix.

About Spherix
Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by active participation in the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation.

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Investor Relations Contact:
Hayden IR
Brett Maas
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

Spherix Contact:
Phone: (703) 992-9325
Email: info@spherix.com
www.spherix.com

(CMLS) Conference Call to Discuss Q4 FY14 Operating Results

ATLANTA, Feb. 3, 2015  — Cumulus Media Inc. (Nasdaq:CMLS) will host a conference call on Monday, March 2^nd at 4:30 PM EST to discuss its fourth quarter and full year 2015 operating results. The call will be open to the general public on a listen-only basis.  A press release containing a summary of these results will be issued before the call at approximately 4:00 PM EST on March 2, 2015.

The conference call dial-in number for domestic callers is 877-830-7699, and international callers should dial 660-422-3366 for call access.

Please call five to ten minutes in advance to ensure that you are connected prior to the presentation.  The call also may be accessed via webcast at www.cumulus.com.

Following completion of the call, a replay can be accessed until 11:30 PM EDT on April 2, 2015. Domestic callers can access the replay by dialing 855-859-2056, replay code 76116091#. International callers should dial 404-537-3406 for conference replay access. 

About Cumulus Media:

Cumulus Media (Nasdaq:CMLS) combines high-quality local programming with iconic, nationally syndicated media, sports and entertainment brands in order to deliver premium choices for listeners, provide substantial reach for advertisers and create opportunities for shareholders. As the largest pure-play radio broadcaster in the United States, Cumulus provides exclusive content that is fully distributed through approximately 460 owned-and-operated stations in 90 U.S. media markets (including eight of the top 10), approximately 8,500 broadcast radio affiliates and numerous digital channels. Cumulus is well-positioned in the widening digital audio space through a significant stake in the Rdio digital music service, featuring over 30 million songs on-demand in addition to custom playlists and exclusive curated channels.  Cumulus is also the leading provider of country music and lifestyle content through its ‎NASH brand, which serves country fans nationwide through radio programming, NASH Country Weekly magazine, concerts, licensed products and television/video. For more information, visit www.cumulus.com

CONTACT: Collin Jones
         Investor Relations
         Cumulus Media Inc.
         404-260-6600

(APRI) Expands Exclusive Marketing License Agreement On Vitaros(R)

Apricus Eligible to Receive an Additional Upfront, Milestone Payment and a Double-Digit Royalty on Net Sales

SAN DIEGO, Feb. 3, 2015  — Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has further expanded its exclusive license agreement with Hexal AG, an affiliate within the Sandoz Division of the Novartis Group of Companies (“Sandoz”), for the commercialization of Vitaros®, Apricus’ novel topical on-demand treatment for erectile dysfunction (“ED”). This amendment is in addition to the in-place collaboration established with Hexal AG in Germany in 2012, and the expansion of the cooperation in 2013 to include Austria, Belgium, Denmark, Finland, Iceland, Luxembourg, the Netherlands, Norway, Sweden and Switzerland. This expanded agreement includes Malaysia, Indonesia, the Philippines, Thailand, Taiwan, Vietnam, Hong Kong and Singapore (the “New Territory”).

In combination with the terms of the previously signed license agreements with Sandoz, Apricus is eligible to receive up to approximately $63.5 million in combined upfront, regulatory and sales milestone payments, which includes up to a total of $6.4 million in upfront and pre-commercialization payments, and a double-digit royalty rate for Vitaros.

“Leveraging our strong working relationships and expanding our existing Vitaros agreements with our collaboration partners is an on-going key initiative within Apricus,” said Richard Pascoe, Chief Executive Officer of Apricus. “Having recently introduced Vitaros in Germany, Belgium and Sweden, Sandoz has set an impressive pace with their launch performance to date, and as such, we are very pleased that they have elected to increase their commitment to Vitaros in these important markets outside of Europe.” Mr. Pascoe continued, “Moreover, we will continue to seek value creating partnerships in other available territories in an effort to bring this novel ED treatment to physicians and patients throughout the world.”

Vitaros is an exciting new entrant into the ED treatment market, offering a range of clear benefits that make it ideal for virtually any ED patient. Vitaros is a topical cream ED medication that delivers rapid onset (generally 5-15 minutes), a treatment duration of approximately 1 hour and an excellent safety profile. Vitaros’ local delivery provides a very attractive alternative for all patients, but particularly those with complications that preclude them from using the orally delivered systemic treatments or who prefer to not use the injectable forms of alprostadil.

According to the most recent estimates, the global ED market in 2013 was in excess of $5.5 billion annually. Vitaros has the potential to generate for Apricus over $215 million in future milestone payments, as well as additional potential royalty revenue on net product sales based upon double-digit royalty rates through its existing commercial partnerships. In addition, Apricus intends to leverage Vitaros through additional licensing efforts in key markets such a Japan and China in Asia and throughout Latin America.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ lead product, Vitaros^®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. Apricus’ marketing partners for Vitaros include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. Apricus’ second-generation Vitaros Room Temperature Device is under development and is expected to enhance the product’s commercial value. The Vitaros trademark is registered or has pending applications for registration in certain countries and jurisdictions around the world. The mark is not registered in all of the countries mentioned above. Apricus recently commenced a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon. Additionally, Apricus plans to initiate a Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of male secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms. Apricus is currently seeking a strategic partner to fund development of Femprox^®, a product candidate for the treatment of female sexual interest/arousal disorder that completed an approximately 400-subject proof-of-concept study.

For further information on Apricus, visit http://www.apricusbio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: references to the planned launches of Vitaros® in various countries by Sandoz; the potential for the product to achieve commercial success generally or in any specific territory; the size of the commercial opportunity for the product; and the timing of Phase 2 clinical trials for fispemifene. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: its ability to further develop its product Vitaros for the treatment of erectile dysfunction, such as the room temperature version of Vitaros, and its product candidates RayVa for the treatment of Raynaud’s phenomenon and fispemifene for the treatment of secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms in men, as well as the timing of such events; Apricus’ ability to carry out clinical studies for RayVa and fispemifene, as well as the timing and success of the results of such studies; potential adverse side effects or other safety risks associated with fispemifene and RayVa that could delay or preclude approval; Apricus’ dependence on its commercial partners to increase sales of Vitaros in various territories, and the potential for delays in the timing of commercial launches in additional countries; competition in the erectile dysfunction market and other markets in which Apricus and its partners operate; Apricus’ ability to obtain license partners for Vitaros; Apricus’ ability to obtain and maintain intellectual property protection for Vitaros, RayVa, fispemifene or any other product candidates; Apricus’ ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; Apricus’ ability to obtain the requisite governmental approval for Vitaros in the New Territory; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus’ most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC’s website at www.sec.gov or without charge from Apricus.

CONTACT: Institutional Investors: Angeli Kolhatkar
         angeli@areciaadvisors.com
         Arecia Advisors
         (917) 387-44770

         Retail Investors: Chris Eddy, David Collins
         apri@catalyst-ir.com
         Catalyst Global
         (212) 924-9800

(REPH) Enters Into Common Stock Purchase Agreement With Aspire Capital

Recro Can Raise Up to $10 Million Over 2 Years

MALVERN, Pa., Feb. 3, 2015  — Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”). Under the new agreement, Recro has the right to sell up to $10 million in shares of common stock to Aspire Capital, subject to certain terms and conditions over a two-year period. The agreement represents an additional tool to provide the Company with additional capital and flexibility.

“While we remain focused on our on-going Dex-IN Phase II trial in acute pain following surgery, this financing provides us with additional financial flexibility in anticipation of our upcoming interim and top-line results for our on-going trial,” said Gerri Henwood, Recro Pharma’s President and Chief Executive Officer. “We believe that having ready access to capital provides us a stronger financial position as we continue our corporate, clinical and operational activities.”

Key terms under the common stock purchase agreement are:

• Recro will control the timing and amount of any sale of common shares to Aspire Capital;
• Aspire Capital has no right to require any sales by Recro but is obligated to make purchases as Recro directs, in accordance with the terms of the purchase agreement;
• There are no limitations on the use of proceeds, financial covenants or restrictions on future financings and there are no rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement; and
• The purchase agreement may be terminated by Recro at any time, at its discretion, without any additional cost or penalty.

A complete and detailed description of the purchase agreement and related registration rights agreement will be set forth in the Company’s Current Report on Form 8-K filed today with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Recro Pharma, Inc.

Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain. Recro Pharma’s lead product candidate, Dex-IN, is a proprietary intranasal formulation of dexmedetomidine and has completed multiple clinical trials in which Dex-IN was well tolerated. As Recro Pharma’s product candidates are not in the opioid class of drugs, the Company believes its candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory distress while maintaining analgesic effect. If approved, Dex-IN would be the first and only approved acute pain drug in its class.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Recro Pharma’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend” and “expect” and similar expressions, as they relate to Recro Pharma or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Recro Pharma as of the date of this press release and are subject to a number of risks, uncertainties, and other factors that could cause Recro Pharma’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. Recro Pharma assumes no obligation to update any such forward-looking statements. Factors that could cause Recro Pharma’s actual results to materially differ from those expressed in the forward-looking statements set forth in this press release include, without limitation: the results and timing of the clinical trials of Dex-IN and any future clinical and preclinical studies; the ability to obtain and maintain regulatory approval of product candidates, and the labeling under any such approval; regulatory developments in the United States and foreign countries; the Company’s ability to raise future financing for continued development; the performance of third-party suppliers and manufacturers; the Company’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection; the successful commercialization of the Company’s product candidates; and the successful implementation of the Company’s strategy. In addition, the forward-looking statements in this press release should be considered together with the risks and uncertainties that may affect Recro Pharma’s business and future results included in Recro Pharma’s filings with the Securities and Exchange Commission at www.sec.gov.

CONTACT: Recro Pharma, Inc.
         Charles T. Garner
         Chief Financial Officer
         (484) 395-2425

         Media and Investors:
         Argot Partners
         Susan Kim
         (212) 600-1902
         susan@argotpartners.com

(MTSL) to Acquire Vexigo Ltd.

RA’ANANA, Israel, February 3, 2015  —

MTS – Mer Telemanagement Solutions Ltd. (Nasdaq Capital Market: MTSL), a global provider of mobile virtual network enabler (MVNE), mobile money and telecommunications expense management (TEM) solutions and services, today announced that it has signed a definitive agreement to acquire Vexigo Ltd. (“Vexigo”), a privately-held Israeli-based software company supporting video advertising over the internet and mobile devices, which will continue to operate as a wholly-owned subsidiary of MTS.

Under the terms of the agreement, MTS will acquire 100% of the outstanding shares of Vexigo. MTS will pay cash consideration of $4 million, consisting of the payment of $3 million at closing and two payments of $500,000 each that will be paid three months and six months following the closing date. In addition, at closing MTS will issue 40% of MTS’s outstanding ordinary shares post-closing to Vexigo’s shareholders. The agreement further provides for earnout payments of up to $16 million over a 5.5 years period from the closing date, based on the earnings of the Vexigo product line.

According to Vexigo’s unaudited financial results as of September 30, 2014, revenues for the nine months period ended September 30, 2014 were $6.6 million, compared with $3.2 million during full year 2013. Operating income for the nine months ended September 30, 2014 was $2.5 million compared with an operating loss of $140 thousand during full year 2013. Net income for the nine months ended September 30, 2014 was $2.2 million compared with a net loss of $119 thousand during full year 2013.

“We are excited about this acquisition which we believe will benefit our customers, partners, employees and shareholders.” said Lior Salansky, CEO of MTS. “With this acquisition, we believe that we will have the scale and resources to expand our market position. The Vexigo team, who will continue their employment with Vexigo after the transaction closes, have developed a compelling technology and built a profitable company that is at the forefront of the online and mobile content visualization and online video advertising business. This new line of business will diversify our existing portfolio of telecom products and services; IoT solutions, cloud solutions and big data solutions. We intend to continue to strengthen our portfolio of products that help customers reduce costs, increase revenues and gain a competitive advantage in their markets.”

“This transaction is in line with our business objectives and it is an important step in carrying out our strategy to enhance our business and increase shareholder value by making accretive acquisitions and entering into new business areas” said Mr. Chaim Mer, Chairman of the Board of the Company.

The acquisition is expected to be completed on or before April 10, 2015. The acquisition is subject to customary closing conditions, including the approval of the transaction at an extraordinary meeting of the shareholders of MTS that is expected to be held in the first quarter of 2015.

About Vexigo

Vexigo (http://www.vexigo.com) is a global provider of online video advertising software and services delivering compelling results through a propriety in-house technology and an easy-to-use and very effective publishing platform specifically designed for content publishers.

Vexigo specializes in video advertising solutions for online and mobile platforms, engaging multiple ad formats and interactive ad units with a cutting-edge, in-house optimization platform providing precise targeting in a safe environment for both advertisers and website owners.

The Vexigo Visualizr is a publishing platform based on proprietary software that allows website owners to showcase their content in the form of an alluring and exciting personalized magazine across all devices, including wearables. With a full suite of monetization tools, the Visualizr is a real breakthrough in content monetization.

About MTS

Mer Telemanagement Solutions Ltd. (MTS) is a global provider of innovative products and services for telecom expense management (TEM), enterprise mobility management (EMM), mobile virtual network operators and enablers (MVNO/MVNE), billing mobile money services and solutions and an IOT/M2M enablement platform used by mobile service providers.

The MTS TEM Suite solution enables enterprises to gain visibility and control of strategic fixed and mobile telecom assets, services and IT security policies that drive key business processes and provides a crucial competitive advantage.  The MTS cloud, consulting and managed services solutions – including integrated management of invoices, assets, wireless, optimization, usage, mobile device management, procurement, help desk and bill payment, along with dashboards and reporting tools – provide professionals at every level of an organization with rapid access to concise, actionable data.

The MTS solution for M2M (Machine to Machine) and Internet of Things (IoT) service providers is a comprehensive, proven and highly scalable cloud-based IoT enablement platform. The platform supports all business, operational, management and analytics services, features and functionality requirements of M2M and IoT service providers.

MTS’s solutions for wireless and wireline telecommunication service providers are used for interconnect billing, partner revenue management and for charging and invoicing services. The MTS MVNE services enable the quick launch of new MVNO initiatives in pay as you grow and revenue share models.  In addition, MTS has pre-configured, full-features and scalable solutions to support emerging carriers of focused solutions (e.g. IPTV, VoIP, WiMAX, MVNO).

Headquartered in Israel, MTS markets its solutions through wholly owned subsidiaries in the United States and Hong Kong and through distribution channels. MTS shares are traded on the NASDAQ Capital Market (symbol MTSL). For more information please visit: http://mtsint.com/

Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, risks in product development plans and schedules, rapid technological change, changes and delays in product approval and introduction, customer acceptance of new products, the impact of competitive products and pricing, market acceptance, the lengthy sales cycle, proprietary rights of the Company and its competitors, risk of operations in Israel, government regulations, dependence on third parties to manufacture products, general economic conditions and other risk factors detailed in the Company’s filings with the United States Securities and Exchange Commission.

Contact:
MTS:
Alon Mualem
CFO
Tel: +972-9-7777-540
Alon.Mualem@mtsint.com

(TBPH) and Mylan Partner to Develop, Commercialize Novel LAMA Compound

Phase 3 registrational studies of TD-4208 are anticipated to begin in 2015

GEORGE TOWN, Grand Cayman and PITTSBURGH, Feb. 2, 2015  — Theravance Biopharma, Inc. (NASDAQ: TBPH) and Mylan Inc. (NASDAQ: MYL) today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.

COPD is a growing and devastating disease that is the third leading cause of death in the U.S.¹ An estimated 12.7 million American adults are diagnosed with COPD and an almost equal number are believed to be undiagnosed.² Once-daily LAMAs are currently the cornerstone of maintenance therapy for patients with COPD, but existing LAMAs are only available in handheld devices. Approximately 9% of the treated COPD patients in the U.S. either need or prefer a nebulized product for delivery of their ongoing maintenance therapy and a further 30% of COPD patients use nebulized treatment on an intermittent basis.³ In the nebulizer segment, there is no once-daily or twice-daily muscarinic antagonist therapy available.

TD-4208 has shown positive top-line results in COPD patients in multiple Phase 2 studies, and the FDA recently agreed to the design of the Phase 3 registrational program, which is anticipated to begin this year. Theravance Biopharma and Mylan believe that TD-4208 has the potential to be a best-in-class once-daily single-agent nebulized product for COPD patients who require, or prefer, nebulized therapy.

“This exciting development and commercialization collaboration leverages Mylan’s expertise in manufacturing and marketing complex respiratory products and Theravance Biopharma’s respiratory clinical development capabilities. The addition of TD-4208 to our pipeline is highly complementary with our existing respiratory portfolio, including our marketed nebulized COPD product, Perforomist® Inhalation Solution, and reinforces Mylan’s leadership in nebulized respiratory therapy,” said Mylan CEO Heather Bresch.

“Partnering with a world leader in nebulized respiratory therapies enables us to expand the breadth of our TD-4208 development program and extend our commercial reach beyond the acute care setting where we currently market VIBATIV® (telavancin). Funding of the Phase 3 registrational program by Mylan strengthens our company’s capital position and enhances our financial flexibility to advance other high-value pipeline assets alongside TD-4208,” said Rick E Winningham, Chairman and Chief Executive Officer, Theravance Biopharma.  “We look forward to working with Mylan to bring this potential first-in-class, once-daily nebulized therapy to COPD patients.”

Under the terms of the agreement, Mylan and Theravance Biopharma will co-develop nebulized TD-4208 for COPD and other respiratory diseases. Theravance Biopharma will lead the U.S. registrational development program and Mylan will be responsible for reimbursement of Theravance Biopharma’s costs for that program up until the approval of the first new drug application, after which costs will be shared. In addition, Mylan will be responsible for commercial manufacturing. In the U.S., Mylan will lead commercialization and Theravance Biopharma will retain the right to co-promote the product under a profit-sharing arrangement. Outside the U.S. (excluding China), Mylan will be responsible for development and commercialization and pay Theravance Biopharma a royalty on net sales. Theravance Biopharma retains worldwide rights to TD-4208 delivered through other dosage forms, such as a metered dose inhaler or dry powder inhaler (MDI/DPI).

In addition to funding the U.S. registrational development program, Mylan will pay Theravance Biopharma an initial payment of $15 million in cash and has agreed to make a $30 million equity investment in Theravance Biopharma by purchasing newly issued Ordinary Shares at a price of $18.92 per share, which is equal to a 10% premium over the 5-day trailing volume-weighted average price ending January 30. Under the terms of the agreement, Theravance Biopharma is eligible to receive potential development and sales milestone payments totaling $220 million in the aggregate, with $175 million associated with TD-4208 monotherapy and $45 million for future potential combination products.

Mylan and Theravance Biopharma believe that TD-4208 has the potential to be the only FDA-approved once-daily nebulized LAMA product for COPD patients in the near term and it may offer longer-term opportunities for combination with other nebulized products. In addition, the patent portfolio for TD-4208 is currently expected to provide a TD-4208 nebulized product with exclusivity in the U.S. until at least 2025, which does not include any potential patent term extensions. Given the short- and long-term potential of this differentiated product, and in an effort to optimize its uses of capital, Mylan has decided to redeploy resources from the development of its combination nebulized ICS/LABA product (Combo) to TD-4208.

About TD-4208

TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) in development for the treatment of chronic obstructive pulmonary disease (COPD). In September 2014, Theravance Biopharma announced positive top-line results from its Phase 2b dose-ranging study of TD-4208. TD-4208 met the primary efficacy endpoint (change from baseline in trough FEV₁ [forced expiratory volume in one second] following the last dose on Day 28) with statistically significant responses at once-daily doses of 88, 175 and 350 mcg. The lowest dose of 44 mcg once-daily produced a sub-therapeutic response that was not statistically different from placebo.

In November 2014, Theravance Biopharma announced positive top-line results from the once- versus twice-daily (QD versus BID) study of TD-4208. The study compared 175 mcg once-daily against 44 mcg twice-daily in a 3-period, 7-day placebo-controlled crossover study conducted in 64 COPD patients. The study met its primary endpoint and demonstrated that the lower dose (44 mcg) administered twice-daily did not produce greater bronchodilation than the higher dose (175 mcg) administered once-daily.  The frequency of adverse events was low and consistent across all three treatments including placebo. There was one death in the study that was assessed by the study investigator as unrelated to study medication.

Conference Call Today at 8:00 am ET

Theravance Biopharma will hold a conference call today at 8:00 am ET to discuss the content of this press release. To participate in the live call by telephone, please dial (855) 296-9648 from the U.S., or (920) 663-6266 for international callers. To listen to the conference call live via the internet, please visit Theravance Biopharma’s website at www.theravance.com, under the Investor Relations section, Presentations and Events. To listen to the live call please go to Theravance Biopharma’s website 15 minutes prior to its start to register, download, and install any necessary audio software.

A replay of the conference call will be available on Theravance Biopharma’s website through March 4, 2015. An audio replay will also be available through 11:59 p.m. ET on February 9, 2015 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and entering confirmation code 79259295.

About Theravance Biopharma  

The mission of Theravance Biopharma (Nasdaq: TBPH) is to create value from a unique and diverse set of assets: an approved product; a development pipeline of late-stage assets; and a productive research platform designed for long-term growth.

Our pipeline of internally discovered product candidates includes potential best-in-class opportunities in underserved markets in the acute care setting, representing multiple opportunities for value creation. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S. and Europe for difficult-to-treat infections. TD-4208 is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for COPD. Axelopran (TD-1211) is a potential once-daily, oral treatment for opioid-induced constipation (OIC). Our earlier-stage clinical assets represent novel approaches for potentially treating diseases of the lung and gastrointestinal tract – our core areas of therapeutic focus – and infectious disease. In addition, we have an economic interest in future payments that may be made by GSK pursuant to its agreements with Theravance, Inc. relating to certain drug programs, including the combination of umeclidinium, vilanterol and fluticasone furoate (or the “Closed Triple”).

With our successful drug discovery and development track record, commercial infrastructure, experienced management team and efficient corporate structure, we believe that we are well positioned to create value for our shareholders and make a difference in the lives of patients.

For more information, please visit www.theravance.com.

THERAVANCE®, the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE® and VIBATIV ® are trademarks and/or registered trademarks of the Theravance Biopharma group of companies. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

This press release contains and the conference call will contain certain “forward-looking” statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance Biopharma intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: the strategies, plans and objectives of Theravance Biopharma, the status and timing of clinical studies, data analysis and communication of results, the potential benefits and mechanisms of action of TD-4208, the enabling capabilities of Theravance Biopharma’s approach to drug discovery and Theravance Biopharma’s proprietary insights, expectations for TD-4208 through development and commercialization, the timing of seeking regulatory approval of TD-4208 and the duration of intellectual property protection for TD-4208. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of the press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: the disruption of operations during the transition period following the spin-off of Theravance Biopharma from Theravance, Inc., including the diversion of management’s and employees’ attention from the business, adverse impacts upon the progress of discovery and development efforts, disruption of relationships with collaborators and increased employee turnover, delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate TD-4208 is unsafe or ineffective, dependence on third parties to conduct clinical studies, delays or failure to achieve and maintain regulatory approvals for TD-4208, and risks of collaborating with third parties to develop and commercialize TD-4208. Other risks affecting Theravance Biopharma are described under the heading “Risk Factors” contained in Theravance Biopharma’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 12, 2014. In addition to the risks described above and in Theravance Biopharma’s other filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 25,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. Learn more at mylan.com.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

This press release includes statements that constitute “forward-looking statements,” including with regard to sales of products; product development, studies and potential; product markets; and the company’s strategy, future growth and performance. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impacts of competition; changes in economic and financial conditions of the company’s business; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; risks associated with international operations; uncertainties and matters beyond the control of management; and the other risks detailed in the company’s filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

References :

^1. American Lung Association. “Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet.” http://www.lung.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.html. Accessed on January 26, 2015.

^2. American Thoracic Society. “Center for Patients & Families: The Basics of Lung Disease/Lung Disease 101 Fact Sheet.” http://patients.thoracic.org/?page_id=8. Accessed on January 26, 2015.

^3. Market research conducted by Theravance Biopharma, Inc.

(MEET) Achieves Record-High Mobile DAU in January

MeetMe, Inc. (NASDAQ: MEET), the public market leader for social discovery, has achieved a new milestone, averaging more than one million daily active users (DAU) on mobile for the first month of this year. The widely popular and fast-growing app also set a new record for user-to-user chats, averaging more than 21 million per day for the month.

“We are thrilled to start 2015 off with record traffic and engagement,” said Geoff Cook, CEO of MeetMe. “Our mobile traffic is up nearly 30% from January a year ago. We look forward to continuing to execute against a strong product pipeline as we seek to build the pre-eminent mobile chat app for connecting with new people.”

About MeetMe, Inc.

MeetMe® is the leading social network for meeting new people in the US and the public market leader for social discovery (NASDAQ: MEET). MeetMe makes it easy to discover new people to chat with on mobile devices. With approximately 80 percent of traffic coming from mobile and more than one million total daily active users, MeetMe is fast becoming the social gathering place for the mobile generation. The company is a leader in mobile monetization with a diverse revenue model comprising advertising, native advertising, virtual currency, and subscription. MeetMe apps are available on iPhone, iPad, and Android in multiple languages, including English, Spanish, Portuguese, French, Italian, German, Chinese (Traditional and Simplified), Russian, Japanese, Dutch, Turkish and Korean. For more information, please visit meetmecorp.com.

Cautionary Note Concerning Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including whether our mobile DAU average will grow in the future and if so at what rate, whether the MeetMe App will remain widely popular and fast growing, whether the number of our daily user-to-user chats will grow in the future and if so at what rate, whether we will continue to experience record traffic and engagement, whether mobile traffic will grow in the future and if so at what rate, whether we will execute against our product pipeline as anticipated and the strength of that pipeline, and whether we will successfully build the pre-eminent mobile chat app for connecting with new people. All statements other than statements of historical facts contained herein are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “project,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the risk that our applications will not function easily or otherwise as anticipated, the risk that we will not launch additional features and upgrades as anticipated, the risk that unanticipated events affect the functionality of our applications with popular mobile operating systems, any changes in such operating systems that degrade our mobile applications’ functionality and other unexpected issues which could adversely affect usage on mobile devices. Further information on our risk factors is contained in our filings with the Securities and Exchange Commission (“SEC”), including the Form 10-K for the year ended December 31, 2013, the Prospectus Supplement (Rule 424(b)(5)) filed on July 24, 2014, and the Current Report on Form 8-K filed on December 29, 2014. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

(AXAS) Provides Operations Update; Announces Upcoming Presentation

Abraxas Petroleum Corporation (“Abraxas” or the “Company”) (NASDAQ:AXAS) today provided the following operations update and also announced an upcoming presentation.

Williston Basin

At Abraxas’ North Fork prospect, in McKenzie County, North Dakota, the Stenehjem 3H, producing from the Middle Bakken, averaged 1,057 boepd (848 barrels of oil per day, 1,254 mcf of natural gas per day) ⁽¹⁾ over the well’s peak 30 days of production. The Stenehjem 2H and 4H, producing from the Three Forks, averaged 863 boepd (686 barrels of oil per day, 1,062 mcf of natural gas per day) ⁽¹⁾ over the wells’ peak 30 days of production. In the Jore unit, Abraxas recently set production casing in the lateral of the Jore 5H and 6H, and is preparing to drill the lateral section of the Jore 7H. Abraxas owns a working interest of approximately 73% and 76% in the Stenehjem and Jore wells, respectively.

Eagle Ford

At Abraxas’ Jourdanton prospect in Atascosa County, Texas, the Cat Eye 1H averaged 491 boepd (464 barrels of oil per day, 169 mcf of natural gas per day)⁽¹⁾ over the well’s peak 30 days of production. Since being placed on submersible pump the Cat Eye 1H averaged 587 boepd (552 barrels of oil per day, 211 mcf of natural gas per day)⁽¹⁾ over the following twelve production days. The Cat Eye 1H represents the Company’s first well on the Southern fault block at Jourdanton. Abraxas owns a 100% working interest across the Jourdanton prospect.

At Abraxas’ Dilworth East prospect, in McMullen County, Texas, the Company drilled the R. Henry 1H to a total depth of 16,588 feet. Following the completion of drilling operations on the R. Henry 1H, the Company released its Eagle Ford rig. Abraxas owns a 100% working interest in the R. Henry 1H.

Abraxas recently leased an incremental 204 incremental net acres at the Company’s Dilworth East prospect in McMullen County, Texas. The prospect now consists of a combined 1,148 net contiguous acres and can accommodate up to ten 5,000-5,500 foot laterals and three 8,500 foot laterals.

Upcoming Presentation

Bob Watson, President and CEO of Abraxas, will be presenting at IPAA OGIS Florida on Tuesday, February 3, 2015 at 9:05 AM EST. The presentation will be webcast and can be accessed at http://www.investorcalendar.com/IC/CEPage.asp?ID=173603 or through Abraxas’ website, www.abraxaspetroleum.com.

Bob Watson, President and CEO of Abraxas, commented, “Although it is still quite early, the rates on our first Three Forks downspacing test are very encouraging. If Three Forks downspacing continues to prove successful, this will add an incremental 15 Three Forks locations to our inventory. Alongside our Middle Bakken downspacing test, we believe we have potentially derisked approximately 34 incremental downspaced locations at North Fork and Lillibridge.

“In the Eagle Ford, the Cat Eye 1H is producing at very encouraging rates. As the first well on our Southern Fault block this has meaningful implications for the prospectivity of the remaining 45+ locations on this acreage position. Also in the Eagle Ford, we are excited to announce the acquisition of an incremental 204 net acres at our Dilworth East prospect, which adds three 8,500 foot lateral locations. We continue to look for similar opportunities to expand our asset base in the Eagle Ford and Bakken.”

(1) The production rates for each well do not include the impact of natural gas liquids and shrinkage at the processing plant and include flared gas.

Abraxas Petroleum Corporation is a San Antonio based crude oil and natural gas exploration and production company with operations across the Rocky Mountain, Permian Basin and onshore Gulf Coast regions of the United States.

Safe Harbor for forward-looking statements: Statements in this release looking forward in time involve known and unknown risks and uncertainties, which may cause Abraxas’ actual results in future periods to be materially different from any future performance suggested in this release. Such factors may include, but may not be necessarily limited to, changes in the prices received by Abraxas for crude oil and natural gas. In addition, Abraxas’ future crude oil and natural gas production is highly dependent upon Abraxas’ level of success in acquiring or finding additional reserves. Further, Abraxas operates in an industry sector where the value of securities is highly volatile and may be influenced by economic and other factors beyond Abraxas’ control. In the context of forward-looking information provided for in this release, reference is made to the discussion of risk factors detailed in Abraxas’ filings with the Securities and Exchange Commission during the past 12 months.

(UBIC) & TechLaw Solutions To Demo Big Data Future Discovery At LegalTech New York 2015

UBIC and TechLaw Solutions Technology Demos Will Showcase Their Front-Line E-Discovery Tools: Virtual Data Scientist and Behavior Informatics

NEW YORK, Feb. 2, 2015  — UBIC, Inc. (Nasdaq:UBIC) (TSE:2158), a leading provider of international litigation support and big-data analysis services, and TechLaw Solutions (a UBIC Company) will showcase their cutting-edge products and services at LegalTech New York (LTNY) 2015, Exhibit Hall Booths #1996 and #134 along with their demo room suites.

UBIC and TechLaw Solutions will also present the CLE Eligible Educational Track “Behavior Informatics and Next Generation Business Intelligence: Transforming Governance, Litigation and Data Analysis,” which is presented in three sessions.

Session One, “Pre-Crime is a Reality: Stopping Fraud Before it Happens” (10:30 — 11:45 AM) will feature discussion leader Stephen K. Henn, Esq., Head of North American Operations at UBIC North America, Inc. Expert panelists include: Daniel Lim, Of Counsel at Shook, Hardy & Bacon LLP; Judy Selby, Partner and Co-Chair, Information Governance Team at BakerHostetler; and Jason Ruger, Chief Security Officer at Motorola, a Lenovo Company.

Paul Starrett, Esq., EnCE, CFE, General Counsel at UBIC North America, Inc. will lead the discussion for Session Two “Using Artificial Intelligence to Manage Big Data for Litigation” (2:00 — 3:15 PM). Expert panelists include: Gail Gottehrer, Partner, Axinn, Veltrop & Harkrider LLP; Alvin Lindsay, Partner and Co-Chair, Electronic Information Group at Hogan Lovells; James Sherer Counsel and Co-Chair, Information Governance Team at BakerHostetler; Sonya Strnad, Senior Counsel at Holland & Knight; and James Zucker, Assistant General Counsel, Horizon Blue Cross Blue Shield of New Jersey.

John A. Norris, JD, MBA, Chairman of Norris Capital, Inc. and Food, Drug, Device, and Healthcare, Inc. will lead the Session Three discussion “Behavior Informatics in Healthcare: eMedical Records and Data Security” (3:45 — 5:00 PM). Expert panelists include: Sarah G. Flanagan, Partner at Pillsbury Winthrop Shaw Pittman LLP; Yoshikatsu Shirai, Chief Client Technology Officer at UBIC, Inc.; and Sumio Takeichi, Secretary General, Global Collaboration Center, Advisor, Governor Kanagawa Prefectural Government, Former Director, IFC (Member of The World Bank) Former Director, Mitsubishi Corporation.

To schedule a demo of UBIC and TechLaw Solutions’ E-Discovery Tools please contact Sasha Hefler at sasha_hefler@ubicna.com.

LTNY 15 takes place February 3-5, 2015 at the New York Hilton Midtown. For more information visit: legaltechshow.com

About UBIC

UBIC, Inc. (Nasdaq:UBIC) (TSE:2158) is a leading provider of E-Discovery and digital forensic services for Asia and the world. UBIC has extensive experience working with electronically stored information composed in Chinese, Japanese and Korean (CJK) languages and utilizes that expertise for clients involved in cross-border litigation, corporate investigations, intellectual property disputes and much more. At the forefront of E-Discovery innovation, UBIC’s proprietary Lit i View^® platform is moving the industry from “fact discovery” to “future discovery” by allowing clients to analyze e-mail messages and digital communications found in big data to reveal patterns in human thought and behavior.

For more information about UBIC, contact usinfo@ubicna.com or visit http://www.ubicna.com

CONTACT: Sasha Hefler
         sasha_hefler@ubicna.com

(YOD) Agreement With Twentieth Century Fox Television Distribution In China

NEW YORK, Feb. 2, 2015  — YOU On Demand Holdings, Inc. (NASDAQ: YOD) (“YOU On Demand”), a leading Video On Demand (“VOD”) service provider in China delivering Hollywood movies and premium content to mobile and TV screens, has entered into a licensing agreement with Twentieth Century Fox Television Distribution (“Fox”) for the SVOD rights in China to a broad selection of library feature films.

The titles will be available to subscribers of YOU On Demand’s Subscription VOD (SVOD) platform and service, via mobile, Over-the-Top (OTT), digital cable and IPTV.

Some of the movies that will be available to YOU On Demand customers include recent worldwide box office hits and award winners such as: A-Team starring Bradley Cooper and Liam Neeson; Black Swan starring Academy Award winner, Natalie Portman; 10-time Academy Award nominated film, Master and Commander, starring Russell Crowe; Speed, starring Sandra Bullock and Keanu Reeves; Unstoppable, starring Denzel Washington and Chris Pine.

“Twentieth Century Fox’s award-winning and blockbuster films demonstrate YOU On Demand’s continued commitment to deliver the best premium content to our customers,” said Shane McMahon, Chairman of YOU On Demand.  “We are excited to be working with them in China as we bring their diverse library to all YOU On Demand platforms.”

Gina Brogi, Executive Vice President of Worldwide Pay TV & SVOD at Twentieth Century Fox Television Distribution, added, “We are very pleased that this agreement with YOU On Demand will see many of our high quality feature films become accessible to viewers in China via the company’s breakthrough SVOD service.”

About Twentieth Century Fox Television Distribution
A unit of 21st Century Fox, Twentieth Century Fox Television Distribution is a global leader in the distribution of award-winning motion pictures, television programming and entertainment content across pay-TV, broadcast television and SVOD.  Twentieth Century Fox Television Distribution connects audiences around the world with premium content from the production divisions of Twentieth Century Fox Films, Twentieth Century Fox Television and FX, as well as other 21st Century Fox companies.

About YOU On Demand Holdings, Inc. (http://corporate.yod.com)
YOU On Demand (NASDAQ: YOD), is a leading multi-platform entertainment company delivering premium content, including leading Hollywood movie titles, to customers across China via Subscription Video On Demand and Transactional Video On Demand. The Company has secured alliances with leading global media operators and content developers.  YOU On Demand has content distribution agreements in place with many of Hollywood’s top studios including Disney Media Distribution, Paramount Pictures, NBC Universal, Twentieth Century Fox Television Distribution, Miramax Films, Lionsgate and Magnolia Pictures, as well as a broad selection of the best content from Chinese filmmakers. The Company has a comprehensive end-to-end secure delivery system, governmental partnerships and approvals and offers additional value-added services. YOU On Demand has strategic partnerships with the largest media entities in China, a highly experienced management team with international background and expertise in Cable, Television, Film, Digital Media, Internet and Telecom. YOU On Demand is headquartered in New York, NY with its China headquarters in Beijing.

CONTACT:
Jason Finkelstein
YOU On Demand
212-206-1216
jason.finkelstein@yod.com
@youondemand

(OHGI) Initiates Coverage with Price Target of $4.05

NEW YORK, NY / February 2, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has initiated coverage of One Horizon Group, Inc. (NASDAQ: OHGI) with Price Target of $4.05.

“OHGI provides mobile carriers with a complete, white-labeled solution that includes a mobile VoIP app that is offered under the carriers’ own brand. The company also offers a robust advertising platform that can deliver one-to-many or one-to-one ads and promotions, including location-based ads using GPS. OHGI’s platform helps carriers by making them relevant players in the rapidly growing mobile VoIP space while also recapturing revenues that are currently being diverted by third party Over the Top apps. The advertising platform can then be used to expand revenue opportunities across the subscriber base,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $4.05 per share.”

The report is available here: OHGI Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Additional highlights from the report are as follows:

Proprietary VoIP solution solves carrier bandwidth issues

The explosion in the smartphone and tablet markets has caused an exponential increase in data traffic over the past few years. Maintaining and upgrading networks to meet this demand presents a large problem an enormous cost for mobile carriers. OHGI has developed software application platforms that optimize mobile voice, instant messaging and advertising communications over the internet, collectively, the “Horizon Platform”. The Horizon Platform is the world’s most bandwidth-efficient VoIP platform, and it is based off of OHGI’s proprietary SmartPacket(TM) technology. Smartpacket(TM) enables greater bandwidth efficiency by reducing IP overhead and optimizing packet flow, delivery and playback. This technology can significantly decrease the strain on a carrier’s network while also providing demonstrated cost savings to the carrier through its increased efficiency. The 2013 Cisco VNI report estimated that global mobile data traffic will increase nearly 11x between 2013-2018, a 61% CAGR. By the end of 2014, the number of mobile-connected devices will exceed the number of people on earth, and by 2018 there will be nearly 1.4 mobile devices per capita.

White label solution for carriers to combat over the top apps

Fueling the growth of data traffic and diverting revenue streams from telecommunications carriers has been the growth of over the top (“OTT”) applications. In the mobile world, apps such as WhatsApp, Viber and WeChat have become increasingly popular as an alternative to traditional SMS text messaging and have grown in popularity as their features, such as sharing pictures and videos, have expanded. These OTT apps have allowed 100’s of millions of subscribers to circumvent traditional mobile operators’ platforms. Consulting firm Ovum Ltd has estimated that OTT apps cost carriers $23.6 billion in 2013 and see that figure rising to $86 billion by 2020. OHGI offers mobile carriers a white label solution to brand their own OTT app and recapture lost customer revenue. In addition, OHGI provides carriers and enterprises with a powerful advertising platform to incorporate into their OTT app and expand revenue per subscriber.

Tier 1 customers and large backlog bode well for 2015

During 4Q14, OHGI announced agreements with two Tier 1 customers (defined as having a potential user market of over 50 million subscribers). The company finished 3Q14 with an order backlog of $56.1mn. This provides excellent visibility heading into 2015.

Please review important disclosures on our website at www.seethruequity.com.

About One Horizon Group, Inc.

One Horizon Group Inc.’s business is to optimize communications over the Internet through its wholly owned subsidiary, Horizon Globex GmbH, Baar, which develops and markets one of the world’s most bandwidth-efficient mobile voice over Internet Protocol (VoIP) platforms for smartphones, and also offers a range of other optimized data applications including messaging and mobile advertising. Horizon Globex GmbH is an ISO 9001 and ISO 20000-1 certified company. The Company has operations in Switzerland, the United Kingdom, China, India, Singapore, Hong Kong and Ireland.

For more information on the Company, its products and services, please visit www.onehorizongroup.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com